Treatment with 17 beta-estradiol protects donor heart against brain death effects in female rat
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Citação
TRANSPLANT INTERNATIONAL, v.33, n.10, p.1312-1321, 2020
Resumo
The viability of donor organs is reduced by hemodynamic and immunologic alterations caused by brain death (BD). Female rats show higher heart inflammation associated with the reduction in female sex hormones after BD. This study investigated the effect of 17 beta-estradiol (E2) on BD-induced cardiac damage in female rats. Groups of female Wistar rats were assigned: Sham-operation (Sham), brain death (BD), treatment with E2 (50 mu g/ml, 2 ml/h) 3 h after BD (E2-T3), or immediately after BD confirmation (E2-T0). White blood cell (WBC) count was analyzed; cytokines and troponin-I were quantified. Heart histopathological changes and expression of endothelial nitric oxide synthase, endothelin-1, intercellular adhesion molecule-1, BCL-2, and caspase-3 were evaluated. Cardiac function was continuously assessed for 6 h by left ventricular pressure-volume loop analysis. E2 decreased the BD-induced median serum concentration of troponin-I (BD:864.2 vs. E2-T0:401.4;P = 0.009), increased BCL-2 (BD:0.086 vs. E2-T0:0.158; P = 0.0278) and eNOS median expression in the cardiac tissue (BD:0.001 vs. E2-T0:0.03 and E2-T3:0.0175; P < 0.0001), and decreased caspase-3 (BD:0.025 vs. E2-T0:0.006 and E2-T3:0.019; P = 0.006), WBC counts, leukocyte infiltration, and hemorrhage. 17 beta-estradiol treatment was effective in reducing cardiac tissue damage in brain-dead female rats owing to its ability to reduce leukocyte infiltration and prevent cardiomyocyte apoptosis.
Palavras-chave
brain death, estradiol, female Wistar rats, heart, inflammation
Referências
- Borbely XI, 2015, NEUROCRIT CARE, V23, P66, DOI 10.1007/s12028-014-0101-x
- Breithaupt-Faloppa AC, 2016, J SURG RES, V200, P714, DOI 10.1016/j.jss.2015.09.018
- Chen CW, 2017, J HEART LUNG TRANSPL, V36, P611, DOI 10.1016/j.healun.2017.02.001
- Correia CD, 2019, SHOCK, V51, P495, DOI 10.1097/SHK.0000000000001169
- De Santo LS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120813
- Ferreira SG, 2018, INFLAMMATION, V41, P1488, DOI 10.1007/s10753-018-0794-7
- Francischetti I, 2010, REV BRAS CIR CARDIOV, V25, P575, DOI 10.1590/S0102-76382010000400023
- Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200
- Hsieh CH, 2008, J IMMUNOL, V181, P2806, DOI 10.4049/jimmunol.181.4.2806
- Kaczmarek I, 2013, THORAC CARDIOV SURG, V61, P29, DOI 10.1055/s-0032-1331467
- Khush KK, 2012, J HEART LUNG TRANSPL, V31, P459, DOI 10.1016/j.healun.2012.02.005
- Lopez SP, 2008, TRANSPLANTATION, V86, P977, DOI 10.1097/TP.0b013e318186d6d6
- Luo T, 2016, CAN J CARDIOL, V32, P1017, DOI 10.1016/j.cjca.2015.10.021
- Magalhaes DMS, 2019, J SURG RES, V235, P8, DOI 10.1016/j.jss.2018.09.058
- Muller V, 1999, KIDNEY INT, V55, P2011, DOI 10.1046/j.1523-1755.1999.00441.x
- Patten RD, 2004, CIRC RES, V95, P692, DOI 10.1161/01.RES.0000144126.57786.89
- Simao RR, 2016, ACTA CIR BRAS, V31, P278, DOI 10.1590/S0102-865020160040000009
- Simas R, 2012, CLINICS, V67, P69, DOI 10.6061/clinics/2012(01)11
- Szabo G, 2004, J HEART LUNG TRANSPL, V23, pS223, DOI 10.1016/j.healun.2004.04.005
- Vieira RF, 2018, J HEART LUNG TRANSPL, V37, P1381, DOI 10.1016/j.healun.2018.06.015
- Wang MJ, 2009, AM J PHYSIOL-REG I, V296, pR972, DOI 10.1152/ajpregu.00045.2009
- Weiss ES, 2009, CIRC-HEART FAIL, V2, P401, DOI 10.1161/CIRCHEARTFAILURE.108.844183
- Wilhelm MJ, 2000, J HEART LUNG TRANSPL, V19, P414, DOI 10.1016/S1053-2498(00)00073-5
- Yeager ME, 2012, AM J RESP CELL MOL, V46, P14, DOI 10.1165/rcmb.2010-0506OC
- Yeh T, 1999, J THORAC CARDIOV SUR, V117, P365, DOI 10.1016/S0022-5223(99)70435-6